Kemoterapia säteilyllä tai ilman leikkausta oligometastaattisen ruokatorven tai mahasyövän hoidossa
Satunnaistettu tutkimus, jossa verrataan varhaista paikallista kemoterapiahoitoa +/- leikkausta verrattuna systeemiseen hoitoon potilailla, joilla on ruokatorven tai mahasyöpä, joilla on oligometastaasseja
This phase II trial studies how well chemotherapy with or without radiation or surgery works in treating participants with esophageal or gastric cancer that has spread to less than 3 places in the body (oligometastatic). Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Surgery, such as complete surgical resection, may stop the spread of tumor cells by surgically removing organs or tumors. Giving chemotherapy with radiation or surgery may work better than chemotherapy alone in treating participants with oligometastatic esophageal or gastric cancer.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
PRIMARY OBJECTIVES:
I. To evaluate whether esophageal or gastric patients with oligometastatic cancer without disease progression after first line chemotherapy therapy will demonstrate improved overall survival (OS) with early local therapy (concurrent chemotherapy/radiation and surgery).
SECONDARY OBJECTIVES:
I. Assess the relationships between progression-free survival and overall survival between both treatment arms.
II. Report local control, loco-regional control. III. Report time to progression of distant metastases. IV. Report toxicity.
OUTLINE:
Participants receive induction chemotherapy for a minimum of 6 cycles and a maximum of 8 cycles in the absence of disease progression or unacceptable toxicity. Participants are then randomized to 1 of 2 groups.
GROUP I (MAINTENANCE CHEMOTHERAPY): Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.
GROUP II (LOCAL THERAPY): Participants receive fluorouracil and capecitabine and undergo radiation therapy (RT) per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.
After completion of study treatment, participants are followed up at 4-8 weeks, 2-3 months, every 3-6 months for up to 3 years, and then every 6-12 months thereafter.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Quynh Nhu Nguyen, MD
- Puhelinnumero: 713-563-2300
- Sähköposti: qnnguyen@mdanderson.org
Opiskelupaikat
-
-
Texas
-
Houston, Texas, Yhdysvallat, 77030
- Rekrytointi
- M D Anderson Cancer Center
-
Ottaa yhteyttä:
- Quynh-Nhu Nguyen
- Puhelinnumero: 713-563-2300
-
Päätutkija:
- Quynh-Nhu Nguyen
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
The patient has a pathologic diagnosis of tumor biopsy or FNA of esophageal or gastric cancer of adenocarcinoma histology
-
The patient is staged with EGD and PET/CT scan.
-
The patient has three or less observable metastatic lesions. Patients may have three or less radiographically visible metastatic lesions at diagnosis or if have regressed to three or less metastatic lesions after induction chemotherapy at time of randomization. The patient must have pathologic confirmation and or radiologically visible disease. For esophageal tumors, the maximal dimension of the primary tumor may not provide reproducible measurements for RECIST and may not be visible on CT or PET/CT at diagnosis or after induction chemotherapy. Accordingly, patients are eligible regardless of the imaging measurements of the primary tumor. Additionally, in patients with non-measurable metastases, patients are eligible if there is pathology confirming metastases from a distant site. However, biopsy of a metastatic site is not required if there are visible metastases on imaging (such as ultrasound, diagnostic CT , EUS, PET/CT).
- The patient has three or less observable metastatic lesions by diagnostic scans (CT scan, PET/CT, eEndoscopic ultrasound, MRI, or bone scan). Metastatic lesions include distant M1 lymph node group; which will be counted as one site (M1 metastatic lymph nodes to include cervical, mediastinal, gastric, retroperitoneal lymph nodes will be counted as one lesion).
- Osseous metastases or visceral metastases will each count as one metastatic site.
- Each CNS metastases will count as one metastatic site.
- Satellite lesions in the primary esophageal malignancy such as skipped esophageal primaries are not considered metastatic sites. Symptomatic metastatic sites can be treated locally prior to randomization or by palliative radiation.
- Symptomatic metastatic sites may be treated with radiation or surgery prior to enrollment.
-
Patient ECOG of 0-2, with life expectancy of at least 6 months
-
Patients age >18 yrs old but <80 yrs old and signed informed consent
-
Women of child-bearing age must have pregnancy test at time of enrollment, agree to use of adequate contraception (birth control hormone or barrier method) for the duration of the study and for six months after discontinuation of systemic agents.
Exclusion Criteria:
-
Patients with prior chemotherapy or radiation therapy for their diagnosis of esophageal or gastric cancer. Patients with prior radiation therapy to same site for another diagnosis of cancer. Note: Patients may receive palliative radiation to their symptomatic sites of metastases but not definitive local therapy to esophageal or gastric primary prior to randomization. All patients may be enrolled on protocol then start systemic therapy; if they do not have evidence of disease progression at re-staging following initial therapy, they may be randomized.
-
Patients with fistula documented radiographically or by EDG/EUS, EBUS.
-
Patients with life expectancy less than 6 months, ECOG >3
-
Female patients who are pregnant confirmed by bHCG lab test.
-
Patient has history of uncontrolled angina, congestive heart failure or recent MI within 6 months.
-
Nursing females
-
Patients in poor nutritional state
-
Patients with:
- Severely depressed bone marrow function
- Potentially serious infections
- Known hypersensitivity to 5-fluorouracil
- Known or suspected to have a dihydropyrimidine dehydrogenase deficiency (as these patients are at a greater risk of experiencing symptoms of toxicity)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Group I (maintenance chemotherapy)
Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. |
Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
Muut nimet:
Receive induction chemotherapy
Muut nimet:
Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
Muut nimet:
|
|
Kokeellinen: Group II (local therapy)
Participants receive fluorouracil and capecitabine and undergo RT per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician. |
Undergo surgery Undergo RT
Muut nimet:
Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
Muut nimet:
Receive induction chemotherapy
Muut nimet:
Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Overall survival (OS)
Aikaikkuna: Up to 6 years
|
OS distributions in the two arms will be estimated by the method of Kaplan and Meier. Bayesian piecewise exponential regression will be used to assess the relationships between each of OS and PFS, and patients' covariates and treatment arm. |
Up to 6 years
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Local progression-free survival (PFS)
Aikaikkuna: Up to 6 years
|
PFS distributions in the two arms will be estimated by the method of Kaplan and Meier. Bayesian piecewise exponential regression will be used to assess the relationships between each of OS and PFS, and patients' covariates and treatment arm. |
Up to 6 years
|
|
Distant PFS
Aikaikkuna: Up to 6 years
|
PFS distributions in the two arms will be estimated by the method of Kaplan and Meier. Bayesian piecewise exponential regression will be used to assess the relationships between each of OS and PFS, and patients' covariates and treatment arm. |
Up to 6 years
|
|
Incidence of adverse events
Aikaikkuna: Up to 6 years
|
Graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. |
Up to 6 years
|
|
Time to local or regional disease recurrence
Aikaikkuna: Up to 6 years
|
To be analyzed by Bayesian piecewise regression to assess their relationships with treatment arm and prognostic covariates. |
Up to 6 years
|
Muut tulostoimenpiteet
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Time to local disease recurrence
Aikaikkuna: Up to 6 years
|
To be analyzed by Bayesian piecewise regression to assess their relationships with treatment arm and prognostic covariates. |
Up to 6 years
|
|
Time to disease progression
Aikaikkuna: Up to 6 years
|
To be analyzed by Bayesian piecewise regression to assess their relationships with treatment arm and prognostic covariates. |
Up to 6 years
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Yhteistyökumppanit
Yhteistyökumppanit
Tutkijat
Tutkijat
- Päätutkija: Quynh-Nhu Nguyen, M.D. Anderson Cancer Center
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat sivustoittain
- Neoplasmat
- Ruoansulatuskanavan kasvaimet
- Ruoansulatuskanavan kasvaimet
- Ruoansulatuskanavan sairaudet
- Ruoansulatuskanavan sairaudet
- Vatsataudit
- Pään ja kaulan kasvaimet
- Ruokatorven sairaudet
- Vatsan kasvaimet
- Ruokatorven kasvaimet
- Ruokatorven adenokarsinooma
- Heterosykliset yhdisteet, 1-rengas
- Heterosykliset yhdisteet
- Terapeuttiset lääkkeet
- Nukleiinihapot, nukleotidit ja nukleosidit
- Fyysiset ilmiöt
- Deoksisytidiini
- Syytidiini
- Pyrimidiininnukleosidit
- Pyrimidiinit
- Nukleosidit
- Urasiili
- Pyrimidinonit
- Deoksihiobonukleosidit
- Kapesitabiini
- Fluorourasiili
- Sädehoito
- Säteily
- Lääkehoito
- dehydroftorafur
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- 2016-0972
- 2016-0972 (Muu tunniste: M D Anderson Cancer Center)
- NCI-2018-01202 (Rekisterin tunniste: CTRP (Clinical Trial Reporting Program))
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .